Abstract
Introduction: We have recently shown that quitting smoking AFTER a diagnosis of lung cancer is associated with a reduction in mortality by 17% at 1 year(1). Our multi-site study (NCT01192256) now reports changes in Performance status (PS) in continued smokers versus quitter.
Methods: Prospective, observational cohort study of 1134 patients in the UK with newly diagnosed non-small cell lung cancer. We recorded self-reported smoking status, validated with eCO(ppm) readings, at baseline and each follow-up visit until death for up to 2 years. PS was measured by the six-point Eastern Cooperative Oncology Group (ECOG) score.
Cessation treatments were offered according to local services. Data was recorded on study case report forms and confirmed from hospital records and cancer databases. Missing data was removed at each time point and analysed with STATA.
Results: 290 (25.6%) were smokers at baseline and 84 (29%) of these quit over the period.
There were no differences in proportion of surviving people with each ECOG stage 0-3 between ‘Smokers’ and ‘Continuers’ at baseline (p=0.59), 1 month (p=0.67), 3 months (p=0.67), 6 months (p=0.32), 12 months (p=0.89) and 24 months (p=0.17).
Conclusion: There were no differences in ECOG at any time point nor change form baseline between continued smokers versus quitters with NSCLC but numbers, especially over 2 years are very small.
Our observational study continues with larger numbers (now more than 3000 at baseline) at each time point.
1. Gemine, Rachel E., et al. Lung Cancer, 2019, Vol.129, p.1
Footnotes
Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3064.
This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2020
